MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
InfuSystem Holdings Income Statement 2011-2026 | INFU
Annual Income Statement InfuSystem Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
146 M | 236 M | 343 M | 170 M | 81 M | 54.6 M | 53.2 M | 62.8 M | 61.1 M | 61.5 M | 34.7 M | 41.9 M |
Shares |
20.6 M | 20.5 M | 20.1 M | 19.7 M | 21.4 M | 22.7 M | 22.6 M | 22.4 M | 22.2 M | 21.9 M | 21.4 M | 21.1 M |
Historical Prices |
7.07 | 11.5 | 17.1 | 10.6 | 4.04 | 2.25 | 2.2 | 3.2 | 2.64 | 2.64 | 1.62 | 2.03 |
Net Income |
18 K | 1.42 M | 17.3 M | 1.36 M | -1.1 M | -20.7 M | -222 K | 3.74 M | 3.36 M | 1.67 M | -1.49 M | -45.4 M |
Revenue |
110 M | 102 M | 97.4 M | 81.1 M | 67.1 M | 71.1 M | 70.5 M | 72.1 M | 66.5 M | 62.3 M | 58.8 M | 54.6 M |
Cost of Revenue |
47.3 M | 42.2 M | 38.6 M | 34.2 M | 27.6 M | 18.4 M | 16.2 M | 13.8 M | 12.2 M | 11.3 M | 9.16 M | 9.13 M |
Gross Profit |
62.6 M | 60.2 M | 58.8 M | 46.9 M | 39 M | 43.4 M | 44.7 M | 51.2 M | 47.4 M | 43.7 M | 42.9 M | 35.4 M |
Operating Income |
1.65 M | 2.82 M | 8.83 M | 3.52 M | 415 K | -3.81 M | 974 K | 7.28 M | 9.33 M | 5.9 M | 2 M | -66.4 M |
Interest Expense |
1.4 M | 1.38 M | 1.26 M | 1.9 M | 1.42 M | 1.33 M | 1.34 M | 1.7 M | 3.13 M | 3.5 M | 3.34 M | 2.19 M |
EBITDA |
15 M | 17.4 M | 22.9 M | 8.63 M | 5.83 M | 2.74 M | 4.82 M | 11.7 M | 11.8 M | 8.51 M | 4.73 M | 3.9 M |
Operating Expenses |
60.9 M | 57.4 M | 49.9 M | 42.7 M | 37.8 M | 46.2 M | 43.8 M | 42.3 M | 38 M | 37.8 M | 40.9 M | 34.1 M |
General and Administrative Expenses |
46.1 M | 42.3 M | 35.2 M | 28.3 M | 24.1 M | 25.2 M | 24.6 M | 23.8 M | 20 M | 19 M | 23.1 M | 18 M |
All numbers in USD currency
Quarterly Income Statement InfuSystem Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
20.4 M | 20.8 M | 21.1 M | 21.3 M | 21.3 M | 21.3 M | 21.2 M | 21.2 M | 21.1 M | 21 M | 20.9 M | 20.8 M | 20.7 M | 20.6 M | 20.6 M | 20.7 M | 20.6 M | 20.5 M | 20.3 M | 20.3 M | 20.2 M | 20.1 M | 19.9 M | 19.9 M | 19.8 M | 19.7 M | 19.6 M | 19.6 M | 20.7 M | 22.7 M | 22.8 M | 22.8 M | 22.8 M | 22.7 M | 22.7 M | 22.7 M | 22.6 M | 22.6 M | 22.5 M | 22.5 M | 22.4 M | 22.4 M | 22.3 M | 22.3 M | 22.2 M | 22.1 M | 22 M | 22 M | 21.9 M | 21.9 M | 21.8 M | 21.8 M | 21.6 M | 21.2 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M |
Net Income |
2.26 M | 2.6 M | -267 K | - | 1.81 M | 717 K | -1.11 M | - | 689 K | 435 K | -324 K | - | 443 K | -164 K | -368 K | - | -448 K | 820 K | 661 K | - | 2.94 M | 4.14 M | -418 K | - | 1.14 M | 381 K | -960 K | - | -519 K | -505 K | 204 K | - | -129 K | -1.11 M | -1.48 M | - | 56 K | 153 K | 41 K | 1.52 M | 1.14 M | 642 K | -519 K | - | 852 K | 886 K | 583 K | - | 649 K | 105 K | 51 K | - | 33 K | -828 K | -915 K | - | -16.6 M | -27.9 M | -171 K |
Revenue |
36.5 M | 36 M | 34.7 M | - | 35.3 M | 33.7 M | 32 M | - | 31.9 M | 31.7 M | 30.4 M | - | 27.3 M | 27 M | 26.8 M | - | 26.6 M | 24.8 M | 24.5 M | - | 25.1 M | 26 M | 21.6 M | - | 21.5 M | 19.7 M | 18.2 M | - | 16.7 M | 16.4 M | 16.5 M | - | 17.6 M | 16.9 M | 17.7 M | - | 17.2 M | 18.1 M | 18.3 M | 18.7 M | 18.3 M | 16.9 M | 16.7 M | - | 16.6 M | 16.4 M | 17.2 M | - | 15.7 M | 14.7 M | 14.7 M | - | 14.2 M | 14.1 M | 14.3 M | - | 14.5 M | 13.1 M | 13 M |
Cost of Revenue |
15.7 M | 16.1 M | 15.5 M | - | 16.3 M | 17 M | 15.5 M | - | 16.3 M | 15.9 M | 15.4 M | - | 11.1 M | 12.1 M | 11.4 M | - | 11.3 M | 9.78 M | 9.89 M | - | 10 M | 10 M | 8.89 M | - | 9.25 M | 8.37 M | 7.85 M | - | 7 M | 6.73 M | 6.25 M | - | 4.45 M | 4.62 M | 4.54 M | - | 4.02 M | 4.79 M | 3.51 M | - | 3.58 M | 3.66 M | 3.02 M | - | 3.22 M | 2.91 M | 2.89 M | - | 2.75 M | 2.84 M | 2.58 M | - | 2.38 M | 2.15 M | 2.24 M | - | 2.35 M | 2.17 M | 2.14 M |
Gross Profit |
20.8 M | 19.9 M | 19.2 M | - | 19 M | 16.7 M | 16.5 M | - | 15.6 M | 15.8 M | 15 M | - | 16.2 M | 14.9 M | 15.4 M | - | 15.3 M | 15 M | 14.6 M | - | 15.1 M | 16 M | 12.7 M | - | 12.2 M | 11.4 M | 10.3 M | - | 9.67 M | 9.69 M | 10.2 M | - | 11 M | 10.3 M | 10.6 M | - | 10.4 M | 11.1 M | 12.6 M | 13.2 M | 12.9 M | 11.6 M | 11.9 M | - | 11.7 M | 11.9 M | 12.1 M | - | 11.3 M | 10.3 M | 10.4 M | - | 10.2 M | 10.3 M | 10.4 M | - | 9.23 M | 8.99 M | 9.05 M |
Operating Income |
3.81 M | 3.78 M | 618 K | - | 3.26 M | 1.86 M | -845 K | - | 1.7 M | 1.25 M | -107 K | - | 943 K | 207 K | -525 K | - | -351 K | 696 K | 873 K | - | 3.25 M | 4.51 M | 33 K | - | 1.66 M | 971 K | -420 K | - | -95 K | -204 K | 588 K | - | 560 K | -1.09 M | -1.97 M | - | 576 K | 438 K | 414 K | 2.49 M | 2.33 M | 1.08 M | 1.38 M | - | 2.44 M | 2.34 M | 1.78 M | - | 1.92 M | 861 K | 652 K | - | 921 K | 29 K | -513 K | - | -22.5 M | -43.4 M | 227 K |
Interest Expense |
-54 K | 42 K | -29 K | - | -4 K | -63 K | 3 K | - | -14 K | 2 K | 484 K | - | 385 K | 314 K | 277 K | - | 270 K | 317 K | 322 K | - | 283 K | 332 K | 403 K | - | 488 K | 488 K | 460 K | - | 370 K | 296 K | 315 K | - | 354 K | 333 K | 328 K | - | 384 K | 327 K | 305 K | - | 338 K | 387 K | 672 K | - | 752 K | 776 K | 827 K | - | 838 K | 924 K | 874 K | - | 971 K | 663 K | 601 K | - | 541 K | 564 K | 541 K |
EBITDA |
7.1 M | 7.12 M | 3.94 M | - | 6.41 M | 4.89 M | 2.06 M | - | 4.76 M | 4.34 M | 3.1 M | - | 4.38 M | 3.61 M | 2.89 M | - | 3.39 M | 4.36 M | 4.44 M | - | 6.81 M | 8.04 M | 3.44 M | - | 4.79 M | 3.99 M | 2.48 M | - | 5 K | 961 K | 1.78 M | - | 660 K | 295 K | -558 K | - | 1.53 M | 1.36 M | 1.33 M | 2.49 M | 2.43 M | 1.18 M | 1.48 M | - | 2.54 M | 2.44 M | 1.88 M | - | 2.02 M | 961 K | 752 K | - | 1.02 M | 129 K | -413 K | - | -20.8 M | -41.8 M | 1.78 M |
Operating Expenses |
17 M | 16.1 M | 18.5 M | - | 15.8 M | 14.8 M | 17.3 M | - | 13.9 M | 14.6 M | 15.1 M | - | 15.3 M | 14.7 M | 15.9 M | - | 15.6 M | 14.4 M | 13.7 M | - | 11.9 M | 11.5 M | 12.6 M | - | 10.6 M | 10.4 M | 10.8 M | - | 9.77 M | 9.89 M | 9.65 M | - | 10.5 M | 11.4 M | 12.6 M | - | 9.81 M | 10.7 M | 12.1 M | - | 10.5 M | 10.5 M | 10.5 M | - | 9.29 M | 9.58 M | 10.3 M | - | 9.42 M | 9.47 M | 9.77 M | - | 9.28 M | 10.2 M | 10.9 M | - | 31.7 M | 52.4 M | 8.83 M |
General and Administrative Expenses |
14.4 M | 13.1 M | 15.3 M | - | 12.8 M | 11.5 M | 13.7 M | - | 10.9 M | 11.4 M | 11.6 M | - | 11.8 M | 10.9 M | 11.8 M | - | 11.6 M | 10.6 M | 10.4 M | - | 8.59 M | 7.71 M | 8.65 M | - | 6.94 M | 6.88 M | 7.13 M | - | 6.29 M | 6.4 M | 6.16 M | - | 5.56 M | 6.42 M | 6.46 M | - | 5.27 M | 6.39 M | 6.67 M | - | 5.68 M | 5.99 M | 5.98 M | - | 4.92 M | 4.9 M | 4.91 M | - | 4.58 M | 5.01 M | 5.03 M | - | 5.28 M | 6.14 M | 6.27 M | - | 4.46 M | 4.25 M | 4.52 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company InfuSystem Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
$ 19.11 | -0.98 % | $ 9.75 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 194.07 | -0.8 % | $ 55.8 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 8.64 | -18.34 % | $ 174 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.67 | 1.66 % | $ 28.4 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
$ 78.81 | -0.64 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
$ 5.81 | 2.11 % | $ 265 M | USA |
 |
AtriCure
ATRC
|
$ 39.56 | -1.54 % | $ 1.86 B | USA |
 |
ICU Medical
ICUI
|
$ 142.67 | -1.36 % | $ 3.48 B | USA |
 |
electroCore
ECOR
|
$ 4.49 | -3.55 % | $ 24.8 K | USA |
 |
iRhythm Technologies
IRTC
|
$ 177.44 | -0.63 % | $ 5.54 B | USA |
 |
AngioDynamics
ANGO
|
$ 12.84 | -1.23 % | $ 525 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
The Cooper Companies
COO
|
$ 81.96 | -0.62 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 112.91 | -1.16 % | $ 5.47 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 81.1 | -2.3 % | $ 1.82 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 80.15 | -1.02 % | $ 4.03 B | USA |
 |
Nephros
NEPH
|
$ 4.88 | 3.39 % | $ 50.7 M | USA |
 |
Masimo Corporation
MASI
|
$ 130.06 | -0.77 % | $ 6.93 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 88.14 | -0.47 % | $ 5.13 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 566.36 | -1.09 % | $ 201 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.42 | -2.02 % | $ 180 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.0 | -2.44 % | $ 20.4 M |  Israel |
 |
Milestone Scientific
MLSS
|
$ 0.27 | -0.22 % | $ 21.5 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 21.71 | -0.91 % | $ 3.74 B | USA |
 |
Pro-Dex
PDEX
|
$ 38.48 | -0.3 % | $ 127 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 32.4 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 13.73 | 0.22 % | $ 660 M | USA |
 |
ResMed
RMD
|
$ 240.87 | -0.91 % | $ 35.2 B | USA |
 |
Repligen Corporation
RGEN
|
$ 163.86 | -1.64 % | $ 9.13 M | USA |
 |
BioLife Solutions
BLFS
|
$ 24.18 | -1.95 % | $ 1.11 B | USA |
 |
STERIS plc
STE
|
$ 253.52 | -0.76 % | $ 25 B | USA |
 |
Stereotaxis
STXS
|
$ 2.3 | -0.22 % | $ 186 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.77 | -0.63 % | $ 23.1 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 23.09 | -0.52 % | $ 1.13 B | USA |
 |
Utah Medical Products
UTMD
|
$ 55.96 | -0.57 % | $ 203 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 122.04 | 0.35 % | $ 5.72 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.43 | 0.35 % | $ 2.32 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 275.14 | -0.62 % | $ 20.1 B | USA |